0001209191-22-031791.txt : 20220525 0001209191-22-031791.hdr.sgml : 20220525 20220525090908 ACCESSION NUMBER: 0001209191-22-031791 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220523 FILED AS OF DATE: 20220525 DATE AS OF CHANGE: 20220525 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fletcher Aaron G.L. CENTRAL INDEX KEY: 0001789490 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 22959319 MAIL ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-23 0 0001645460 Cue Biopharma, Inc. CUE 0001789490 Fletcher Aaron G.L. C/O CUE BIOPHARMA INC. 40 GUEST STREET BOSTON MA 02135 1 0 0 0 Common Stock 2022-05-23 4 P 0 150000 3.52 A 885000 I See footnote Common Stock 2022-05-24 4 P 0 55000 3.34 A 940000 I See footnote Common Stock 165000 D Common Stock 8867 I By Spouse The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.31 to $3.62. The price reported in Column 4 is a weighted average price. The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4. The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.21 to $3.52. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Cue Biopharma, Inc., any stockholder of Cue Biopharma, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3). /s/ Aaron Fletcher by Colin Sandercock, attorney-in-fact 2022-05-25